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1. Introduction 
 Renal Cell Carcinoma (RCC), also known as 
hypernephroma is a kidney cancer that originates in the lining of the 
proximal convoluted tubule, the very small tubes in the kidney that filter 
the blood and remove waste products. RCC is the most common type of 
kidney cancer in adults, responsible for approximately 80% of cases. It is 
also known to be the most lethal of all the genitourinary tumors. It is 
most likely to spread to neighboring lymph nodes, the lungs, the liver, the 
bones, or the brain. The metastatic stage of renal cell carcinoma occurs 
when the disease invades and spreads to other organs. This presents a 
special challenge to oncologists, as about 70% of patients develop 
metastases during the course of their disease. 
                  
 
                                             Figure 1:  Renal cell carcinoma 
1.1 Epidemiology:  
From 1975 to 2006, the incidence of kidney cancer rose 2% 
annually in the United States. The American Cancer Society estimated 
that by 2015 there would be much  more than 57,760 cases (35,430 in 
males and 22,330 in females) of malignant tumors of the kidney 
diagnosed, with 12,890 deaths (8,160 in males and 4,820 in females). The 
incidence in men is greater than in women (1.6:1).Renal cell cancer 
accounted for 80% of this incidence and mortality. It is more common in 
people of Northern European ancestry (Scandinavians) and North 
Americans than in those of Asian or African descent.  
1.2 Etiology 
 The main causative factors for RCC are Cigarette smoking, 
Obesity, Hypertension, Phenacetin-containing analgesics taken in large 
amounts. 
1.3 Symptoms 
The symptoms include - Abdominal pain, Back pain, Blood in 
the urine, Enlargement of the veins around a testicle (varicocele), 
Swelling or enlargement of the abdomen, and Unintentional weight loss. 
 
2. Sorafenib tosylate 
 Chemically Sorafenib is 4-[4-[[4-chloro-3-(trifluoromethyl) 
phenyl]carbamoylamino] phenoxy] -N-methyl-pyridine-2-carboxamide. 
It is a new smaller molecule, multi-kinase inhibitor for the treatment of 
patients with advanced renal cell carcinoma (RCC). Sorafenib received 
FDA regular approval on December 20, 2005 for the treatment of 
advanced RCC. The phase III Treatment Approaches in Renal cancer 
Global Evaluation Trial (TARGET) indicated that sorafenib is effective and 
well tolerated in advanced renal cell carcinoma patients. The long-term 
treatment with sorafenib is associated with continued efficacy and a well-
tolerated safety profile.  
2.1 Characteristics 
Sorafenib tosylate occurs as white to pale yellow colored, 
tasteless and odorless crystalline powder and is insoluble in water. Its 
molecular formula is C21H16ClF3N4O3 and has a molecular weight of 
464.825. 
The recommended daily dose of Sorafenib is 400 mg (200 mg twice a 
day) atleast 1 hour before or 2 hours after a meal. 
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Figure 2:  Chemical Structure 
 
2.2 Mechanism of action 
Sorafenib is a protein kinase inhibitor that decreases tumor 
cell proliferation in vitro. Sorafenib was shown to inhibit multiple 
intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases 
(VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases 
are thought to be involved in tumor cell signaling, angiogenesis, and 
apoptosis. Sorafenib inhibited tumor growth and angiogenesis of human 
hepatocellular carcinoma and renal cell carcinoma 
2.3 Pharmacological actions  
Sorafenib was highly efficacious in vivo in renal tumour 
xenograft models (RENCA model). Antitumor efficacy was also 
demonstrated in vivo in a number of different non-renal tumour 
Xenograft models by affecting the RAS/RAF/MEK pathway. This included 
xenograft models of human colon, lung, breast, melanoma, leukemia, 
pancreas and ovary. The efficacy of Sorafenib against this tumour models 
suggested that a RAF kinase inhibitor may have utility not only in human 
tumours containing RAS and/or b-RAF mutations, but also in tumours 
that over express other growth factor receptors that signal through the 
same pathway. 
 Furthermore, Sorafenib was very effective against the MV4-11 
AML model that expresses an activating Flt3 mutation. In cellular assays 
in vitro, sorafenib inhibited the RAF/MEK/ERK pathway in breast, 
pancreatic, melanoma, and colon tumour lines as evidenced by reduction 
of phospho-ERK levels including cell lines expressing either wild-type or 
mutant k-RAS or BRAF. However, inhibition of the RAF/MEK/ERK 
pathway was not observed in the non-small cell lung cancer (NSCLC) 
lines A549 and H460, at concentrations up to 20 μm sorafenib. The 
mechanism underlying the lack of Inhibition of ERK phosphorylation in 
these cell lines has not been elucidated. No direct comparison was made 
non-clinically between a tumour model that expresses a wild type VHL 
and a VHL mutant sub line of the same model.  
Sorafenib was active against the 786-0 human renal tumour 
model that has a VHL deletion and was less active against the CAKI-1 
human renal tumour model that expresses wild type VHL. However, since 
these two tumour lines were derived independently from separate 
patients, it could not be concluded that the difference in VHL status was 
solely responsible for the different sensitivity to sorafenib. Although this 
data could help to predict the sensitivity of a human tumour to sorafenib 
therapy, limited data did not support patient selection for sorafenib 
treatment based on this biomarker. The results suggested that sorafenib 
can be combined with paclitaxel, irinotecan, gemcitabine, gefitinib and 
cisplatin with no significant increase in the toxicity and without 
diminishing their antitumor efficacy. However, the combination of 
sorafenib and doxorubicin required reduction of the dose level of both 
agents to attain acceptable tolerance and efficacy.   
2.4 Pharmacokinetics of Sorafenib 
Absorption 
Following oral administration, sorafenib reaches peak plasma 
levels in approximately 3 hours. When given with a moderate-fat meal, 
bioavailability was similar to that in the fasted state. With a high-fat meal, 
sorafenib bioavailability was reduced by 29% compared to 
administration in the fasted state.  
Distribution 
 In vitro binding of Sorafenib to human plasma proteins is 
99.5%. Human serum albumin, α-globulin and the low density 
lipoprotein are the main binding proteins. Sorafenib was equally 
distributed between plasma and blood cells.The binding of Sorafenib to 
plasma is dependent on pH. The fraction unbound decreased to 0.165% 
at pH 7.99 and increased to 1.80% at acidic pH 6.78. 
Metabolism 
Sorafenib is metabolized primarily in the liver, undergoing 
oxidative metabolism, mediated by CYP3A4, as well as glucuronidation 
mediated by UGT1A9. Sorafenib accounts for approximately 70-85% of 
the circulating analytes in plasma at steady-state. Eight metabolites of 
sorafenib have been identified, of which five have been detected in 
plasma as N-oxide, shows in vitro potency similar to that of sorafenib. 
This metabolite comprises approximately 9-16% of circulating analytes 
at steady-state. 
Excretion 
Following oral administration of a 100 mg dose of a solution 
formulation of sorafenib, 96% of the dose was recovered within 14 days, 
with 77% of the dose excreted in feces, and 19% of the dose excreted in 
urine as glucuronidated metabolites. Unchanged sorafenib, accounting 
for 51% of the dose, was found in feces but not in urine. 
2.5 Drug Interactions 
The drugs namely Docetaxel, doxorubicin and Fluorouracil 
requires adjustment of dose when co-administered with sorafenib. 
2.6 Adverse Drug Reactions 
Hand-foot skin reaction and rash represent the most common 
adverse reactions attributed to sorafenib. They   generally appear during 
the first six weeks of treatment .Permanent discontinuation of therapy 
due to hand-foot skin reaction may be required  in few cases.  
2.7 Over dosage 
There is no specific treatment for intake of overdose. The 
highest dose studied clinically is 800 mg twice daily. The adverse 
reactions observed at this dose were primarily diarrhea and 
dermatologic. No information is available on symptoms of acute overdose 
in animals because of the saturation of absorption in oral acute Toxicity 
studies conducted in animals. In cases of suspected overdose, sorafenib 
should be withheld and supportive care instituted. 
2.8 Therapeutic Indications 
Sorafenib is indicated for the treatment of patients with 
advanced renal cell carcinoma, hepatocellular carcinoma (HCC) and 
Differentiated thyroid carcinoma (DTC) that is refractory to radioactive 
iodine treatment. 
 
3. Use in specific populations 
3.1 Pregnancy 
Based on its mechanism of action and findings in animals, 
Sorafenib caused embryo-fetal toxicities in animals at maternal 
exposures that were significantly lower than the human exposures at the 
recommended dose of 400 mg twice daily. There are no adequate and 
well-controlled studies in pregnant women using the drug. The effects 
occurred at doses considerably below the recommended human dose of 
400 mg twice daily (approximately 500 mg/m /day on a body Surface 
area basis). Adverse intrauterine development effects were seen at doses 
≥0.2 mg/kg/day (1.2 mg/m /day) in rats and 0.3 mg/kg/day (3.6 mg/m 
/day) in rabbits.  
3.2 Nursing Mothers 
It is not known whether sorafenib is excreted in human milk. 
Because many drugs are excreted in human milk and because of the 
potential for serious adverse reactions in nursing infants from sorafenib, 
a decision should be made whether to discontinue nursing or to 
discontinue the drug, taking into account the importance of the drug to 
the mother. Following administration of radio labeled sorafenib to 
lactating Wistar rats, approximately 27% of the radioactivity was 
secreted into the milk. The milk to plasma AUC ratio was approximately 
5:1. 
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3.3 Pediatric Use 
The safety and effectiveness of Nexavar in pediatric patients 
have not been studied. repeated dosing of sorafenib to young and 
growing dogs resulted in irregular thickening of the femoral growth plate 
at daily sorafenib doses ≥ 600 mg/m (approximately 0.3 times the AUC at 
the recommended human dose), hypocellularity of the bone marrow 
adjoining the growth plate at 200 mg/m /day (approximately 0.1 times 
the AUC at the recommended human dose), and alterations of the dentin 
composition at 600 mg/m /day. Similar effects were not observed in 
adult dogs when dosed for 4 weeks or less. 
3.4 Geriatric Use: 
In total, 59% of HCC patients treated with Nexavar were age 
65 years or older and 19% were 75 and older. In total, 32% of RCC 
patients treated with Nexavar were age 65 years or older and 4% were 
75 and older. No differences in safety or efficacy were observed between 
older and younger Patients and other reported clinical experience has 
not identified differences in responses between the elderly and younger 
patients, but greater sensitivity of some older individuals cannot be ruled 
out.  
  
4. Conclusion  
The long-term treatment with sorafenib is associated with 
continued efficacy and a well-tolerated safety profile. It can be used in 
combination with other antineoplastic drugs effectively. Sorafenib was 
teratogenic and induced embryo-fetal toxicity. However treatment with 
sorafenib prolongs progression-free survival in patients with advanced 
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